Amend Surgical is advancing orthobiologics science with novel bone graft substitutes including the bone graft product line NanoFUSE® Bioactive Matrix.

ALACHUA, FLORIDA, UNITED STATES, July 26, 2016 /EINPresswire.com/ -- ALACHUA, FL – July 26, 2016 – Amend Surgical, Inc., a medical device company focused on the healing and regenerative capacity of bone grafts, has been admitted into the Sid Martin Biotechnology Institute, the leading biotechnology incubator at the University of Florida. The company was cofounded in June 2015 by Ronald R. Cobb, PhD, and Robby Lane. Amend Surgical is manufacturing and developing a product portfolio of natural and synthetic bone graft substitutes that will disrupt and shift the global orthobiologics market.

Orthobiologics Market Opportunity and Amend Surgical Business Development

Of the more than three million musculoskeletal procedures performed annually in the US, about half involve bone grafting.¹ The global bone graft substitute market was valued at $1.9 billion in 2010 and is forecast to reach $3.3 billion in 2017.²

In December of last year Amend Surgical acquired the rights to an FDA approved, patent protected bone graft product line, NanoFUSE® Bioactive Matrix. The product will be distinct in the orthobiologics market because of its unique and powerful combination of 45S5 Bioactive Glass and demineralized allograft bone matrix. As a part of the acquisition Amend Surgical also received the rights to NanoFuse® BA which will be submitted to the FDA for approval in 2016. Company management’s extensive experience and network within the global spine, orthopedic and dental fields will facilitate rapid adoption for both of these foundation products.

Amend Surgical CEO Robby Lane said, “Our goal is to advance the science of orthobiologics with novel and disruptive bone graft substitutes. The Sid Martin Biotechnology Institute will provide Amend Surgical the foundational support necessary to continue and expand our robust commercialization and research initiatives.”

Mark S. Long, Director of Sid Martin Biotechnology Institute, stated, “Here at the Institute we specialize in helping startups that are developing and introducing new innovations and solutions. We are happy to welcome Amend Surgical. With the company’s expertise, they are on an upward trajectory to new growth and expansion.”

The Sid Martin Biotechnology Institute has facilitated the launch and acceleration of more than 60 successful companies that have garnered over $13.5 billion in venture capital and revenues. The Institute offers startups collaborative, open laboratory workspace combined with financial, technical and human resources to nuture startups’ growth and success.

Amend Surgical was admitted to the Institute’s bio-business program through the fast track admissions process. Prospective startups may submit an inquiry form through the Institute’s website www.sidmartinbio.org and management will make contact to walk them through the admissions process.

About Amend Surgical, Inc.

Amend Surgical, Inc. is a medical device company focused on the healing and regenerative capacity of bone grafts. The company was cofounded in June 2015 by Ronald R. Cobb, PhD, and Robby Lane. Amend Surgical is manufacturing and developing a product portfolio of natural and synthetic bone graft substitutes that will disrupt and shift the global orthobiologics market. For more information, visit www.amendsurgical.com.

About the Sid Martin Biotechnology Institute at the University of Florida

The Sid Martin Biotechnology Institute is the leading biotechnology incubator headquartered at the University of Florida in Alachua, Florida at Progress Park. The Institute has been honored with national and international awards for incubator excellence and achievements in technology commercialization, funding access, job creation and technology-based economic development. It is dedicated to mentoring and accelerating the growth of innovative early-stage bioscience and biotechnology companies, and supporting the economic growth of the North Central Florida region. For more information, visit www.sidmartbio.org.


References:

1. “Bone-graft substitutes in orthopaedic surgery,” A. Jahangir, MD; R. M. Nunley, MD; S. Mehta, MD; A. Sharan, MD; and the Washington Health Policy Fellows, AAOS Now, January 2008.

2. “Bone Graft Substitutes – Global Pipeline, Analysis, Competitive Landscape and Market Forecast to 2017,” Global Data Report, July 2011.


Contacts:
Robby Lane
Chief Executive Officer
Amend Surgical, Inc.
352-226-4988
rlane@amendsurgical.com

Merrie Shaw
UF/Sid Martin Biotechnology Institute
386-462-0880
email us here